Merck & Co has terminated a Phase II/III trial testing its investigational medicine verubecestat in patients with mild to moderate Alzheimer’s disease.
AstraZeneca and Eli Lilly’s experimental Alzheimer’s disease drug AZD3293 has been issued a Fast Track designation in the US potentially speeding up the drug regulatory pathway.